This multicenter, prospective, non-interventional study aims to evaluate data on humoral and cellular immune response generated within the COVID-19 vaccination standard in immunocompromised patients.
This study aims to analyze the immune response data generated within the procedures of the standard-of-care COVID-19 vaccination. for immunocompromised patients. Additional blood will be drawn from the patients at each visit defined within the vaccination standard by using the same vein puncture as used for blood drawings of routine blood samples. Study related blood samples will be used for evaluation of T and B cell response to COVID-19 vaccinations. For this study, no additional visits or invasive procedures will be performed in addition to the standard interventions.
Study Type
OBSERVATIONAL
Enrollment
49
Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation (Med. Klinik IV) Uniklinik der RWTH Aachen
Aachen, North Rhine-Westphalia, Germany
University Hospital of Cologne
Cologne, North Rhine-Westphalia, Germany
Universitätsklinikum Essen Klinik für Hämatologie und Stammzellentransplantation
Essen, North Rhine-Westphalia, Germany
Anti-Spike-IgG titers
Time to an adequate immune response according to the recent version of the COVID-19 vaccination standard after repeated mRNA vaccinations
Time frame: At the end of each vaccination cycle (each cycle is 28 days)
BA.1-specific neutralizing antibody ID50 titers
Time to Omicron BA.1-specific neutralizing antibody ID50 titers ≥20/ml after repeated mRNA vaccinations
Time frame: At the end of each vaccination cycle (each cycle is 28 days)
Anti-Spike-1/2 IgG increase >33.8 BAU/ml
Time to anti-Spike-1/2 IgG increase \>33.8 BAU/ml after repeated mRNA vaccinations in immunocompromised patients
Time frame: At the end of each vaccination cycle (each cycle is 28 days)
Decrease of BA.1-specific neutralizing antibody ID50 titers
Time to decrease of Omicron BA.1-specific neutralizing antibody ID50 titers \<20/ml after last mRNA vaccine in successfully vaccinated patients
Time frame: Every 28 days following last COVID-19 vaccination for a total duration of 24 weeks
Anti-Spike-1/2 IgG decrease ≤33.8 BAU/ml
Time to anti-Spike-1/2 IgG decrease ≤33.8 BAU/ml after last mRNA vaccine in successfully vaccinated patients
Time frame: Every 28 days following last COVID-19 vaccination for a total duration of 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.